VIVUS — Investor Presentation (September 2019)
25 slides from VIVUS's investor presentation, Sep 5, 2019
Slide 1: Forward Looking Statements; Non-GAAP Financial Measures
Forward Looking Statements Non-GAAP Financial Measures Forward Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks, uncertainties and other factors, including risks and unce
Slide 2: About VIVUS
About VIVUS VIVUS is a technology enabled biopharmaceutical company that specializes in the that commercialization of innovative therapies focus on advancing treatments for patients with serious unmet medical needs ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 3
Slide 3: About VIVUS Overview
About VIVUS Overview • VIVUS Health Platform - developing and bringing an integrated approach to care utilizing software integrated with clinical processes to achieve better health outcomes to drive savings in the healthcare system Commercialized Pharmaceuticals o Qsymia (phentermine and topiramate
Slide 4: About VIVUS Brief History
About VIVUS Brief History HISTORY RESET May 1st, 2018 – June 30th, 2018 – Hard Reset GROWTH July 1st, 2018 – Future 1991 – Apr 30th, 2018 • Founded as sexual health biopharmaceutical and device company • IPO in 1993 • Company had four products approved • Multiple CEO’s • Activist shareholders • 2 Co
Slide 5: Completed Four Quarters of a 10-Quarter Turnaround
About VIVUS Completed Four Quarters of a 10-Quarter Turnaround • LTM Q2 2019 Generated $72.7M of revenue and $14.4M of EBITDA o First time since 1997 that VIVUS has generated recurring positive EBITDA o Excluding discretionary R&D expense, VIVUS generated $19.2M of EBITDA Relaunched Qsymia and PANCR
Slide 6: Seizing Opportunity in an Evolving Healthcare Landscape
Strategic Development Seizing Opportunity in an Evolving Healthcare Landscape • The consolidation of PBM’s, health plans, pharmacy chains, wholesalers and data platforms has created a significant chasm between the patient and the pharmaceutical manufacturer The self-insured employer, physician and p
Slide 7: Technology Enablement
Technology Enablement LEGEND VIVUS Health Platform Reusable Needs Modification for Each Product Unique to Each Product Patient Healthcare Provider Q4 2019 Qsymia and PANCREAZE Advantage Programs VIVUS HEALTH Store Vitamins and Supplements Through Amazon Patient Assistance Program Co Pay Card Samplin
Slide 8: VIVUS Health Platform
Strategic Development VIVUS HEALTH PLATFORM Use Case Dependent NUTRITIONAL SCIENCE PHARMACEUTICAL SCIENCE Monitors PATIENT • • • • • • Sleep EKG Weight BMI BP Dietary Inputs ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 9
Slide 9: Pharmaceuticals - Commercial: Qsymia
Pharmaceuticals - Commercial Qsymia is a safe and effective therapy for body mass index management Proprietary extended-release formulation combining low doses of active ingredients from two previously approved compounds, phentermine and topiramate VIVUS believes the 3-month data from its CONQUER st
Slide 10: Pharmaceuticals - Commercial: PANCREAZE
Pharmaceuticals - Commercial • PANCREAZE is indicated for exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions Pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreas glands Provides proven benefits to EPI patients Indicated fo
Slide 11: Pharmaceuticals – Development Stage: VI-0106 PAH
Pharmaceuticals – Development Stage VI-0106 PAH • Tacrolimus for the Treatment of Pulmonary Arterial Hypertension (PAH) ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 12 PAH is a serious, rare, and progressive disease with a 5 Year survival rate of ~22.8% assuming WHO class III/
Slide 12: Tacrolimus: Targeting Proliferation
Pharmaceuticals – Development Stage Tacrolimus: Targeting Proliferation • Bone Morphogenic Protein receptor 2 (BMPR2) signaling inhibits vascular smooth muscle proliferation Reduced BMPR2 expression, including loss-of-function mutations in BMPR2, is prevalent in PAH patients, and may contribute to s
Slide 13: Tacrolimus Experience in PAH Patients
Pharmaceuticals – Development Stage Tacrolimus Experience in PAH patients • Compassionate use o 3 end-stage patients, WHO functional class 3 and 4 o Positive impact on clinical outcomes o Dramatically reduced rate of hospitalizations o Functional class improvements observed Phase 2a study • o o o Ra
Slide 14: Asset Acquisition Philosophy
Acquisitions Asset Acquisition Philosophy • VIVUS is evaluating additional in-licensing and acquisition candidates that would meet its goals of meeting patients’ needs while working toward profitability and creating stockholder value. VIVUS’ approach to evaluating these opportunities • o The price o
Slide 15: Corporate Debt Alternatives
Debt Corporate Debt Alternatives ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 16 In order of current preference 1a Improve operating performance to generate enough recurring cash flow to pay down and refinance debt 1b Acquire asset(s) that generate $25M - $40M of annual non-GA
Slide 16: Debt Bridge June 2019 to May 2020
Debt Debt Bridge June 2019 to May 2020 (in millions) $350 Debt Options $300 Senior Debt $250 New Senior $200 Cash Used $150 $100 New Second Lien $50 Convertible Debt $0 $291.4M of Total Debt June 2018 $181.4M Pay Off Convertible Debt May 2020 $216.4M Total Debt May 2020 $216.4M Total Debt May 2020 •
Slide 17: Experienced Management Team
Overview Experienced Management Team • McKesson, BMS, OTN, BVCF, ORIX, Willow • Johnson & Johnson, Novartis, KRIM, Willow • Deloitte and Touche, Alexza Pharmaceuticals, Pharmacyclics, Incyte, • Wilson, Sonsini, Goodrich and Rosati P.C. • Glaxo Smith Kline, ICC, Novartis • Elan, Merck, Schering Ploug
Slide 18: Management's Focus
Overview Management’s Focus • Drive Qsymia and PANCREAZE revenue and profitability o Qsymia: expand the Qsymia Advantage Program direct-to-patient pharmacy model and launch telemedicine PANCREAZE: continue momentum generated from the Q1 2019 re-launch Growth expected in Q3 2019 o o • Continue addres
Slide 19: Financial Snapshot
Financials Financial Snapshot Company Name Ticker Current Share Price (8/23/2019) 52 Week High 52 Week Low Vivus, Inc VVUS $ $ $ 4.32 7.10 2.15 Plus: Debt (Principal value) Convertible Notes, due 2020 Senior Secured Notes, due 2024 Less Cash and Investments 181.4 110.0 (94.4) Assets Liabilities Rece
Slide 20: Operating Results
Financials Operating Results ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 21 31-Mar-18 30-Jun-18 30-Sep-18 31-Dec-18 QTD QTD QTD QTD Revenue: 2018 (in 000s) 31-Mar-19 30-Jun-19 QTD QTD 2019 YTD LTM Net product revenue $ 9,632 $ 13,250 $ 16,484 $ 17,418 $ 56,784 $ 13,497 $ 15,1
Slide 21: Thank You
Thank You ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 22
Slide 22: Appendix
Appendix ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 23
Slide 23: Business Update: The Next Quarters of Work Underway
Business Update The Next 6 Quarters of Work Underway • Direct-to-patient delivery • Improve formulation for greater shelf life and expanded dose • Telemedicine • Improve reimbursement (i.e. self-insured employers) Russia, MENA) • File IND ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq
Slide 24: Business Update: The Next Quarters of Work Underway
Business Update The Next 6 Quarters of Work Underway Due May 2020 • Drive value through increased EBITDA generation ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 25 Achievements Next Steps Debt • Repurchased $68.6M of Convertible Notes due May 2020 • Address remaining $181.4M o
Slide 25: Business Update: The Next Quarters of Work Underway
Business Update V | V U S The Next 6 Quarters of Work Underway Se eee Debt * Repurchased $68.6M of Convertible Notes due May | > “cress remaining $181.4M of Convertible Notes) Pea Due May 2020 Corporate - 7 . o Adhratsdlaesenusolte Dexama IOS + Acquire additional cash flow generating assets area * D